Literature DB >> 19470575

Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study.

T Okuma1, T Matsuoka, A Yamamoto, S Hamamoto, K Nakamura, Y Inoue.   

Abstract

The aim of this study was to evaluate prospectively the early treatment response after CT-guided radiofrequency ablation (RFA) of unresectable lung tumours by MRI including diffusion-weighted imaging (DWI). The study protocol was approved by the ethics committee of our hospital and signed consent was obtained from each patient. We studied 17 patients with 20 lung lesions (13 men and 4 women; mean age, 69+/-9.8 years; mean tumour size, 20.8+/-9.0 mm) who underwent RFA using a LeVeen electrode between November 2006 and January 2008. MRI was performed on a 1.5T unit before and 3 days after ablation. We compared changes in the apparent diffusion coefficient (ADC) on DWI and response evaluation based on subsequent follow-up CT. 14 of the 20 treatment sessions showed no local progression on follow-up CT, whereas 6 treatment sessions showed local progression (range, 3-17 months; mean, 6 months). For the no-progression group, the ADC pre- and post-RFA were 1.15+/-0.31 x 10(-3) mm(2) s(-1) and 1.49+/-0.24 x 10(-3) mm(2) s(-1), respectively, while the respective ADC values for those that showed local progression were 1.05+/-0.27 x 10(-3) mm(2) s(-1) and 1.24+/-0.20 x 10(-3) mm(2) s(-1). The ADC of the ablated lesion was significantly higher than before the procedure (p<0.05). There was a significant difference in the ADC post-RFA between no-progression and local progression groups (p<0.05). Our prospective pilot study showed that the ADC without local progression was significantly higher than with local progression after RFA, suggesting that the ADC can predict the response to RFA for lung tumours.

Entities:  

Mesh:

Year:  2009        PMID: 19470575      PMCID: PMC3473377          DOI: 10.1259/bjr/13217618

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  24 in total

1.  Percutaneous radiofrequency ablation of malignancies in the lung.

Authors:  D E Dupuy; R J Zagoria; W Akerley; W W Mayo-Smith; P V Kavanagh; H Safran
Journal:  AJR Am J Roentgenol       Date:  2000-01       Impact factor: 3.959

2.  Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis.

Authors:  J F Geschwind; D Artemov; S Abraham; D Omdal; M S Huncharek; C McGee; A Arepally; D Lambert; A C Venbrux; G B Lund
Journal:  J Vasc Interv Radiol       Date:  2000 Nov-Dec       Impact factor: 3.464

3.  Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.

Authors:  Markus Uhl; Ulrich Saueressig; Miriam van Buiren; Udo Kontny; Charlotte Niemeyer; Gabriele Köhler; Kamil Ilyasov; Mathias Langer
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

4.  Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

Authors:  Thierry de Baère; Jean Palussière; Anne Aupérin; Antoine Hakime; Mohamed Abdel-Rehim; Michèle Kind; Clarisse Dromain; Alain Ravaud; Nathalie Tebboune; Valérie Boige; David Malka; Clarisse Lafont; Michel Ducreux
Journal:  Radiology       Date:  2006-08       Impact factor: 11.105

5.  Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization.

Authors:  Jie Deng; Frank H Miller; Thomas K Rhee; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Riad Salem; Reed A Omary; Andrew C Larson
Journal:  J Vasc Interv Radiol       Date:  2006-07       Impact factor: 3.464

6.  Radiologic appearance and complications of percutaneous computed tomography-guided radiofrequency-ablated pulmonary metastases from colorectal carcinoma.

Authors:  Karin Steinke; Julie King; Derek Glenn; David Lawson Morris
Journal:  J Comput Assist Tomogr       Date:  2003 Sep-Oct       Impact factor: 1.826

7.  Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response.

Authors:  Masao Akeboshi; Koichiro Yamakado; Atsuhiro Nakatsuka; Osamu Hataji; Osamu Taguchi; Motoshi Takao; Kan Takeda
Journal:  J Vasc Interv Radiol       Date:  2004-05       Impact factor: 3.464

8.  Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging.

Authors:  Yael Mardor; Raphael Pfeffer; Roberto Spiegelmann; Yiftach Roth; Stephan E Maier; Ouzi Nissim; Raanan Berger; Ami Glicksman; Jacob Baram; Arie Orenstein; Jack S Cohen; Thomas Tichler
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice.

Authors:  Yiftach Roth; Thomas Tichler; Genady Kostenich; Jesus Ruiz-Cabello; Stephan E Maier; Jack S Cohen; Arie Orenstein; Yael Mardor
Journal:  Radiology       Date:  2004-06-23       Impact factor: 11.105

10.  Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report.

Authors:  Jeong Min Lee; Gong Yong Jin; S Nahum Goldberg; Yong Cheol Lee; Gyung Ho Chung; Young Min Han; Sang Yong Lee; Chong Soo Kim
Journal:  Radiology       Date:  2003-11-26       Impact factor: 11.105

View more
  21 in total

Review 1.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 2.  Interventional oncology: the future.

Authors:  Fredric A Hoffer
Journal:  Pediatr Radiol       Date:  2011-04-27

Review 3.  Thermal ablation of lung tumors.

Authors:  P David Sonntag; J Louis Hinshaw; Meghan G Lubner; Christopher L Brace; Fred T Lee
Journal:  Surg Oncol Clin N Am       Date:  2011-04       Impact factor: 3.495

Review 4.  Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer.

Authors:  Oana I Craciunescu; Donald E Thrall; Zeljko Vujaskovic; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 5.  Radiofrequency ablation of lung tumors: imaging features of the postablation zone.

Authors:  Fereidoun G Abtin; Jilbert Eradat; Antonio J Gutierrez; Christopher Lee; Michael C Fishbein; Robert D Suh
Journal:  Radiographics       Date:  2012 Jul-Aug       Impact factor: 5.333

6.  Prospective pilot study of CT-guided microwave ablation in the treatment of osteoid osteomas.

Authors:  Clara Prud'homme; Jean-Philippe Nueffer; Michel Runge; Jonathan Dubut; Bruno Kastler; Sébastien Aubry
Journal:  Skeletal Radiol       Date:  2016-12-27       Impact factor: 2.199

7.  Radiofrequency ablation of advanced lung tumors: imaging features, local control, and follow-up protocol.

Authors:  Ying Wang; Guodong Li; Wentao Li; Xinhong He; Lichao Xu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

9.  Diffusion-weighted magnetic resonance imaging for assessment of lung lesions: repeatability of the apparent diffusion coefficient measurement.

Authors:  L Bernardin; N H M Douglas; D J Collins; S L Giles; E A M O'Flynn; M Orton; N M deSouza
Journal:  Eur Radiol       Date:  2013-11-26       Impact factor: 5.315

10.  Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability.

Authors:  Alex Weller; Marianthi Vasiliki Papoutsaki; John C Waterton; Arturo Chiti; Sigrid Stroobants; Joost Kuijer; Matthew Blackledge; Veronica Morgan; Nandita M deSouza
Journal:  Eur Radiol       Date:  2017-04-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.